Abstract: A method of generating context-customized digital twin is provided. The method includes receiving pieces of basic data by using a data receiver, classifying the pieces of basic data into a plurality of layers and tagging the classified pieces of basic data to tags by using a preprocessor, generating context-customized digital twin models by using pieces of basic data corresponding to tags selected from among the tags by using a twin model generator, and storing the tags, the tagged pieces of basic data, and the context-customized digital twin models in a storage.

Abstract: A cadmium free quantum dot includes zinc, tellurium, and selenium, and lithium. A full width at half maximum of a maximum luminescent peak of the cadmium free quantum dot is less than or equal to about 50 nanometers and the cadmium free quantum dot has a quantum efficiency of greater than 1%.

Abstract: The present invention relates to a novel pyrimidine derivative, and a composition for preventing or treating neurodegenerative diseases and cancer, comprising same, the pyrimidine derivative having a LRRK2 protein inhibitory activity, and effectively passing through a blood-brain barrier (BBB) so as to be effectively used as a pharmaceutical composition for preventing or treating neurodegenerative diseases and cancer.

Abstract: An image sensor substrate includes a semiconductor substrate layer and a semiconductor epitaxial layer on the substrate layer. The semiconductor substrate layer has a boron (B) doping concentration therein in a range from 3×1018 cm?3 to 1×1019 cm?3, whereas the semiconductor epitaxial layer has a boron (B) doping concentration therein in a range from 1×1016 cm?3 to 6×1016 cm?3.

Abstract: The present disclosure relates to a composition that is capable of preventing hair loss and promoting hair growth by comprising the extract of the above-ground part of carrots. The composition comprising the extract of the above-ground part of carrots of the present disclosure significantly increases the viability of dermal papilla cells and can inhibit the expression of 5a-reductase, thereby exhibiting excellent effects in preventing hair loss and promoting hair growth.

Abstract: The present disclosure relates to a microorganism having increased glycine productivity and a method for producing a fermented composition using the microorganism, and more specifically, to a microorganism of the genus Corynebacterium having increased glycine productivity due to the introduction of a mutation in HisG, a method for preparing a fermented composition comprising glycine and glutamic acid using the microorganism of the genus Corynebacterium, and the fermented composition.

Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Abstract: The presented invention relates to a CP2c-targeting peptide-based anticancer agent. A CP2c-targeting peptide according to the presented invention binds to transcription factor CP2c to inhibit the formation of transcription factor CP2c complexes (CP2c homotetramer and CP2c/CP2b/PIAS1 heterohexamer), thereby inducing cancer cell-specific cell death. A fatty acid is bound to the peptide to ensure stability enabling long-term sustenance in vivo.

Abstract: Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing an Fms-like tyrosine kinase (Fms-like tyrosine kinase-3: FLT3) inhibitor or a pharmaceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA) or a pharmaceutically acceptable salt or solvate thereof in a therapeutically effective combination, and a method of treating AML using the composition.

Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Abstract: Provided is a compound selected from a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically acceptable salts of the aforementioned components. The compound is effective in the prevention or treatment of diseases caused by abnormal activation of LSD1. Also disclosed is a composition containing the compound as an active ingredient and its uses in preventing and/or treating diseases caused by abnormal activation of LSD1.

Abstract: Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.

Abstract: Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.

Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Abstract: A novel imidazopyridine derivative compound and uses thereof are disclosed.

Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Abstract: The present invention relates to a novel heterocyclic derivative compound and a use thereof, and in particular, to a novel heterocyclic derivative compound having selective inhibitory activity for a fibroblast growth factor receptor (FGFR) and a pharmaceutical composition including the same preventing and treating various diseases relating to the FGFR.

Abstract: The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.

Abstract: The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.